Cardiology
Latest news
974 articles · 20 / page
Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile
Prophylactic Strategies to Prevent Infection in Lower Limb Peripheral Arterial Reconstruction: Evidence and Clinical Implications
Cochrane review shows prophylactic antibiotics may reduce SSI risk in peripheral arterial reconstruction; closed incision negative pressure therapy offers possible benefit but evidence is low.
Combined Cardiorespiratory and Resistance Training After Stroke: Small Gains, Big Questions
Evidence suggests combined aerobic and strength training post-stroke yields modest improvements in fitness and function but uncertain long-term benefits.
Rare but High-Risk: New-Onset RBBB After TAVR Strongly Linked to Pacemaker Need
New-onset right bundle branch block after TAVR is rare but carries a high risk of requiring permanent pacing within one week.
Prophylactic Pacemakers After TAVR: Low Pacing Burden Raises Questions on Routine Use
One-fourth of TAVR patients receive prophylactic pacemakers, but most have minimal pacing needs at 30 days.
PROMOTE Study Validates Algorithm for Conduction Disturbance Management After TAVR
A prospective multicenter study confirms that a prespecified algorithm for conduction disturbance management after TAVR is safe, with low sudden cardiac death risk but persistent high pacemaker rates.
Distinct Mechanisms Drive Early and Delayed Heart Block After TAVR: Insights from Boston Cohort Study
Prospective cohort study reveals AV nodal versus infranodal conduction patterns underpinning timing of heart block after TAVR.
Riboflavin and Blood Pressure: Evidence Remains Uncertain Despite Genetic Promise
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks
Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.
Beyond the Lesion: Long-Term Cardiovascular, Neurologic, Psychiatric, and Endocrine Risks After Traumatic Spinal Cord Injury
A large retrospective cohort study shows traumatic spinal cord injury (TSCI) is associated with increased long-term cardiovascular, neurologic, psychiatric, and endocrine morbidity and higher mortality, even in previously healthy adults.
Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial
A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a gen
Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies
This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, suppor
Expectant Management Improves Early Survival Without Increasing BPD: Results from the PDA Randomized Clinical Trial
In extremely preterm infants with a protocol-defined PDA, expectant management yielded similar rates of death or BPD at 36 weeks’ postmenstrual age but significantly higher survival compared with active pharmacologic closure.
Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT
A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarker
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, p
VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock
A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infar
Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial
In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding
Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active
Browse by specialty
Open language-specific specialty feeds and department pages.